{'fraction_non_alphanumeric': 0.027632561613144136, 'fraction_numerical': 0.009708737864077669, 'mean_word_length': 5.146788990825688, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
IMMUNE REGULATORY FUNCTION OF INTERFERON-GAMMA IN ACUTE LEUKEMIA

Programmed death ligand-1 (PDL-1) is an immune regulatory component that is expressed on normal cells, tumor cells,
and non-tumor immune cells. The expression of these checkpoint components on the cell surface helps prevent the
immune system's overactivity. PDL-1 is associated with immune evasion in many solid tumors and lymphomas, while its clinical signicance is
under exploration in leukemias. Structural and regulatory aspects are recently presented in reports that dene the role of signaling components in
regulating PDL-1. Immune interactions of soluble cytokines such as IFN-γ & TNF-α with PDL1 show relevance in liquid malignancies. Recent
reports have shown that interaction occurs between IFN- γ and PDL 1, but the exact mechanism is not dened. PDL1 expression around 20-25%
across the malignancies has put this immune checkpoint in clinical trials, and many solid malignancies have shown better clinical outcomes and
survival rates. Still, resistance remains a signicant hurdle. Immune resistance is the primary reason for the minimal impact of PDL-1 blockade
therapy in various cancers. IFN-γ induced PDL1 immunotherapy could be effective in leukemias to overcome the resistance and provide effective
immune responses and overall better clinical outcomes.